Program overview
Context
Indication: Triple-negative Breast Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: VelosBio ., a subsidiary of Merck & Co., . (Rahway, New Jersey USA)
Registry Stop Signal
Zilovertamab vedotin
Zilovertamab vedotin is flagged as registry stop signal because public records show a registry stop signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 5/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 4/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT04504916 | https://clinicaltrials.gov/study/NCT06395103
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT04504916 | Registry Stop Signal (TERMINATED) | None | Low Signal | strict_eligibility_signal |
| NCT06395103 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | None |